New research suggests that patients who come off popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Research printed in a prominent health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month after stopping.
"People purchasing these medications should be informed of the risk of quick weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of recovery implies a reversion to starting mass in about a year and a half.
Comparing Therapies
The analysis, which reviewed 37 of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through lifestyle changes alone generally have a less rapid creep back—around 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Nutrition scientists believe the mechanism of the jabs accounts for the amplified weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than the body's typical production may cause the body to produce less of its endogenous hormone, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making excessive eating much more probable."
A Chronic Issue?
Health authorities advise the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of relapse, the therapy might need to be long-term.
This perspective is echoed by drug manufacturers, who note that the findings "highlight the long-term nature of obesity," akin to managing conditions like hypertension.
User Experiences
Users who have stopped the jabs describe a powerful return of hunger.
"It was like something that goes on and you're instantly ravenous," said one woman.
This difficulty is exacerbated if individuals have not established lasting lifestyle or habit changes during treatment.
Significant Interest
Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is higher among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on ongoing behavioural support.
